CA3171988A1 - Human transferrin receptor binding peptide - Google Patents

Human transferrin receptor binding peptide

Info

Publication number
CA3171988A1
CA3171988A1 CA3171988A CA3171988A CA3171988A1 CA 3171988 A1 CA3171988 A1 CA 3171988A1 CA 3171988 A CA3171988 A CA 3171988A CA 3171988 A CA3171988 A CA 3171988A CA 3171988 A1 CA3171988 A1 CA 3171988A1
Authority
CA
Canada
Prior art keywords
amino acid
peptide
seq
residue
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3171988A
Other languages
English (en)
French (fr)
Inventor
Kenichi Takahashi
Eiji YODEN
Hidehiko Hashimoto
Saki Fujiyama
Masaki OHUCHI
Naoko Nakamura
Nasir Kato Bashiruddin
Naoki SAWAI
Takeru Ehara
Masatoshi TAKUWA
Keiichi Masuya
Shinnosuke Inaba
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JCR Pharmaceuticals Co Ltd
Peptidream Inc
Original Assignee
JCR Pharmaceuticals Co Ltd
Peptidream Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JCR Pharmaceuticals Co Ltd, Peptidream Inc filed Critical JCR Pharmaceuticals Co Ltd
Publication of CA3171988A1 publication Critical patent/CA3171988A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3171988A 2020-02-22 2021-02-22 Human transferrin receptor binding peptide Pending CA3171988A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-028879 2020-02-22
JP2020028879 2020-02-22
PCT/JP2021/006709 WO2021167107A1 (ja) 2020-02-22 2021-02-22 ヒトトランスフェリンレセプター結合ペプチド

Publications (1)

Publication Number Publication Date
CA3171988A1 true CA3171988A1 (en) 2021-08-26

Family

ID=77390874

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3171988A Pending CA3171988A1 (en) 2020-02-22 2021-02-22 Human transferrin receptor binding peptide

Country Status (9)

Country Link
US (1) US20230203098A1 (enExample)
EP (1) EP4108676A4 (enExample)
JP (2) JP7796636B2 (enExample)
CN (1) CN115151556A (enExample)
AU (1) AU2021224412A1 (enExample)
CA (1) CA3171988A1 (enExample)
IL (1) IL295797A (enExample)
TW (1) TW202140513A (enExample)
WO (1) WO2021167107A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2023022234A1 (enExample) * 2021-08-19 2023-02-23
WO2023026994A1 (ja) * 2021-08-21 2023-03-02 武田薬品工業株式会社 ヒトトランスフェリンレセプター結合ペプチド－薬物コンジュゲート
US20240366775A1 (en) 2021-08-24 2024-11-07 Peptidream Inc. Human transferrin receptor binding antibody-peptide conjugate
EP4230638A1 (en) * 2022-02-16 2023-08-23 Lipotrue, S.L. Peptides and compositions for use in cosmetics
WO2024043341A1 (ja) 2022-08-26 2024-02-29 ペプチドリーム株式会社 シクロアルキン誘導体
TWI877887B (zh) * 2022-11-29 2025-03-21 法信諾生醫股份有限公司 轉運胜肽及其應用
TW202434613A (zh) * 2023-02-17 2024-09-01 日商肽夢想股份有限公司 人類運鐵蛋白受體結合肽
EP4682158A1 (en) * 2023-03-17 2026-01-21 FUJIFILM Corporation Cyclic peptide or salt thereof and use thereof
WO2026121297A1 (ja) * 2024-12-04 2026-06-11 ペプチドリーム株式会社 ペプチド及びペイロードを含むコンジュゲート

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60147718A (ja) 1984-01-12 1985-08-03 Seikosha Co Ltd 太陽電池付きカラ−表示素子
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
AU656230B2 (en) * 1991-10-11 1995-01-27 F. Hoffmann-La Roche Ag Cyclic vasoactive peptides
JPH06228199A (ja) 1992-11-27 1994-08-16 Takeda Chem Ind Ltd 血液脳関門通過可能なペプチド結合体
US20090087878A9 (en) * 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
SI1724284T1 (sl) 2000-12-07 2009-12-31 Lilly Co Eli Glp-1 fuzijski proteini
EP1964916B1 (en) 2005-12-06 2012-08-01 The University of Tokyo Multi-purpose acylation catalayst and use thereof
AU2010267963B2 (en) * 2009-07-02 2015-09-24 Merz Pharma Gmbh & Co. Kgaa Neurotoxins exhibiting shortened biological activity
JP5818237B2 (ja) 2010-09-09 2015-11-18 国立大学法人 東京大学 Ｎ−メチルアミノ酸およびその他の特殊アミノ酸を含む特殊ペプチド化合物ライブラリーの翻訳構築と活性種探索法
KR20140026372A (ko) 2011-02-02 2014-03-05 이무노퓨처 아이앤씨. 혈액-뇌 장벽을 투과하는 약물 전달체, 펩티드 및 이의 용도
AU2011367230B2 (en) 2011-05-05 2017-08-10 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
BR112014022435B1 (pt) * 2012-03-21 2023-02-14 Takeda Pharmaceutical Company Limited Inibidores de tfpi e métodos de uso
MX367126B (es) 2012-08-29 2019-08-06 Hoffmann La Roche Transporte para atravesar la barrera hematoencefálica.
EP2952582A4 (en) 2013-01-30 2016-11-16 Peptidream Inc FLEXIBLE DISPLAY METHOD
CN103254280A (zh) * 2013-03-07 2013-08-21 广州暨南大学医药生物技术研究开发中心 具有肿瘤细胞靶向结合能力的短肽及其应用
CA2990785C (en) * 2015-06-24 2024-11-12 Jcr Pharmaceuticals Co., Ltd. ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER
TWI791006B (zh) * 2016-12-26 2023-02-01 日商Ｊｃｒ製藥股份有限公司 包含bdnf之融合蛋白質
CN111683972A (zh) 2018-02-05 2020-09-18 Jcr制药股份有限公司 用于将药剂递送至肌肉的方法

Also Published As

Publication number Publication date
WO2021167107A1 (ja) 2021-08-26
EP4108676A4 (en) 2024-06-05
EP4108676A1 (en) 2022-12-28
US20230203098A1 (en) 2023-06-29
JPWO2021167107A1 (enExample) 2021-08-26
TW202140513A (zh) 2021-11-01
CN115151556A (zh) 2022-10-04
AU2021224412A1 (en) 2022-09-15
JP7796636B2 (ja) 2026-01-09
JP2026032056A (ja) 2026-02-25
IL295797A (en) 2022-10-01

Similar Documents

Publication Publication Date Title
JP7796636B2 (ja) ヒトトランスフェリンレセプター結合ペプチド
KR20220035199A (ko) 인크레틴 유사체의 제조 방법
AU2019218786A1 (en) Cell-permeable stapled peptide modules for cellular delivery
US20240366775A1 (en) Human transferrin receptor binding antibody-peptide conjugate
CN106163569B (zh) 活化的神经降压素分子及其用途
CN118103387A (zh) 肽
EP3433259B1 (en) Conjugates of tacrolimus, their compositions, and their uses
JP2025102922A (ja) 新規ｌｒｐ１結合ペプチド
WO2025116046A1 (ja) ペプチド及び当該ペプチドを含むコンジュゲート
CN107108756A (zh) 细胞穿透性肽
CA3228449A1 (en) Human transferrin receptor binding peptide
HK40083520A (en) Human transferrin receptor binding peptide
US12351652B2 (en) Hemagglutinin-binding peptide
CA3282856A1 (en) Humantransferrin receptor-binding peptide
EP4667483A1 (en) Human transferrin receptor-binding peptide
HK40105891A (en) Human transferrin receptor-binding antibody-peptide conjugate
KR20240045202A (ko) Ghr-결합 펜딩 펩티드 및 이를 포함하는 조성물
HK40105341A (en) Human transferrin receptor–binding peptide
Parlak Peptide-based drug systems

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250210

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250210

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250210

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250214

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250214

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250217

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250506

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20260116

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260209

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260209

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260728